Sector: Healthcare · Industry: 生技醫療業 · Exchange: TPEx
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan.
Headquarters: Zhubei, TW · Website: https://www.medigenvac.com
高端疫苗 (6547) is a publicly traded company in the Healthcare sector (生技醫療業), listed on TPEx. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Competitors of 高端疫苗 (6547) tracked by Macroplane include NVIDIA CORP (NVDA), Alphabet Inc. (GOOGL), Apple Inc. (AAPL), MICROSOFT CORP (MSFT), AMAZON COM INC (AMZN), Broadcom Inc. (AVGO), Samsung Electronics Co., Ltd. (005930.KS), ADVANCED MICRO DEVICES INC (AMD), and 4 more.
Search companies · Macro trends · Industries · Product categories · Baskets